Pseudomonas aeruginosa aggregates in cystic fibrosis sputum produce exopolysaccharides that likely impede current therapies

dc.contributor.authorJennings, Laura K.
dc.contributor.authorDreifus, Julia E.
dc.contributor.authorReichhardt, Courtney
dc.contributor.authorStorek, Kelly M.
dc.contributor.authorSecor, Patrick R.
dc.contributor.authorWozniak, Daniel J.
dc.contributor.authorHisert, Katherine B.
dc.contributor.authorParsek, Matthew R.
dc.date.accessioned2024-10-15T17:45:43Z
dc.date.issued2021-02
dc.description.abstractIn cystic fibrosis (CF) airways, Pseudomonas aeruginosa forms cellular aggregates called biofilms that are thought to contribute to chronic infection. To form aggregates, P. aeruginosa can use different mechanisms, each with its own pathogenic implications. However, how they form in vivo is controversial and unclear. One mechanism involves a bacterially produced extracellular matrix that holds the aggregates together. Pel and Psl exopolysaccharides are structural and protective components of this matrix. We develop an immunohistochemical method to visualize Pel and Psl in CF sputum. We demonstrate that both exopolysaccharides are expressed in the CF airways and that the morphology of aggregates is consistent with an exopolysaccharide-dependent aggregation mechanism. We reason that the cationic exopolysaccharide Pel may interact with some of the abundant anionic host polymers in sputum. We show that Pel binds extracellular DNA (eDNA) and that this interaction likely impacts current therapies by increasing antimicrobial tolerance and protecting eDNA from digestion.
dc.identifier.citationJennings, Laura K., Julia E. Dreifus, Courtney Reichhardt, Kelly M. Storek, Patrick R. Secor, Daniel J. Wozniak, Katherine B. Hisert, and Matthew R. Parsek. "Pseudomonas aeruginosa aggregates in cystic fibrosis sputum produce exopolysaccharides that likely impede current therapies." Cell reports 34, no. 8 (2021).
dc.identifier.doi10.1016/j.celrep.2021.108782
dc.identifier.issn2211-1247
dc.identifier.urihttps://scholarworks.montana.edu/handle/1/18865
dc.language.isoen_US
dc.publisherElsevier BV
dc.rightscc-by
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectPseudomonas aeruginosa biofilm matrix
dc.subjectIHC
dc.subjectexopolysaccharide
dc.subjectPsl
dc.subjectPel
dc.subjectcystic fibrosis
dc.subjectantibiotic susceptibility
dc.subjectbiofilm
dc.subjectbacterial aggregation
dc.subjectextracellular DNA
dc.titlePseudomonas aeruginosa aggregates in cystic fibrosis sputum produce exopolysaccharides that likely impede current therapies
dc.typeArticle
mus.citation.extentfirstpage1
mus.citation.extentlastpage14
mus.citation.issue8
mus.citation.journaltitleCell Reports
mus.citation.volume34
mus.relation.collegeCollege of Agriculture
mus.relation.departmentMicrobiology & Cell Biology
mus.relation.universityMontana State University - Bozeman

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
jennings-cystic-fibrosis-therapies-2021.pdf
Size:
3.24 MB
Format:
Adobe Portable Document Format

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
825 B
Format:
Item-specific license agreed upon to submission
Description:
Copyright (c) 2002-2022, LYRASIS. All rights reserved.